PMID- 30962672
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 13
DP  - 2019
TI  - Long-term efficacy and safety of infliximab and cyclosporine combination therapy 
      for refractory uveoretinitis in Behcet's disease.
PG  - 521-527
LID - 10.2147/OPTH.S198648 [doi]
AB  - PURPOSE: This study aimed to evaluate the long-term efficacy and safety of 
      infliximab (IFX) and cyclosporine (CsA) combination therapy for refractory 
      uveoretinitis in Behcet's disease (BD). PATIENTS AND METHODS: The study involved 
      a retrospective review of the medical records of 11 patients with Behcet's 
      uveoretinitis refractory to conventional treatment who had been treated with 
      IFX+CsA combination therapy. The frequency of ocular inflammatory attacks and a 
      Behcet's disease ocular attack score 24 (BOS24) were used as indices for the 
      evaluation of efficacy during each 6-month period prior to and following 
      initiation of therapy. For the assessment of safety, adverse events (AEs) were 
      recorded throughout the treatment period. RESULTS: The patients had received 
      IFX+CsA combination therapy for 5.6+/-2.3 years. The frequency of ocular attacks 
      per 6-month period decreased markedly from 2.9+/-1.6 during the baseline period to 
      0.6+/-0.9 during months 1-6, 0.5+/-0.9 during months 7-12, 0.3+/-0.5 during months 
      13-18, 0.3+/-0.7 during months 19-24, and 0.0+/-0.0 thereafter (P=0.003). The BOS24 
      score per ocular attack significantly decreased from 5.2+/-2.4 during the baseline 
      period to 1.5+/-2.1 during months 1-6, 1.7+/-3.1 during months 7-12, 1.6+/-2.9 during 
      months 13-18, and 0.4+/-1.0 during months 19-24 (P=0.002). No serious AEs were 
      observed, with the exception of urinary tract infection and cataract progression. 
      Two patients exhibited transient elevation of the serum creatinine level, which 
      was normalized following a reduction in the dose of CsA. CONCLUSION: For 
      refractory Behcet's uveoretinitis, IFX+CsA combination therapy offers a promising 
      treatment option as it appears to have an acceptable safety profile and can 
      reduce the frequency and severity of ocular inflammatory attacks over a long 
      period of time.
FAU - Katsuyama, Atsuko
AU  - Katsuyama A
AD  - Department of Surgery, Division of Ophthalmology, Kobe University Graduate School 
      of Medicine, Chuo-ku, Kobe 650-0017, Japan, kusu@med.kobe-u.ac.jp.
FAU - Kusuhara, Sentaro
AU  - Kusuhara S
AD  - Department of Surgery, Division of Ophthalmology, Kobe University Graduate School 
      of Medicine, Chuo-ku, Kobe 650-0017, Japan, kusu@med.kobe-u.ac.jp.
FAU - Nishisho, Ryuto
AU  - Nishisho R
AD  - Department of Surgery, Division of Ophthalmology, Kobe University Graduate School 
      of Medicine, Chuo-ku, Kobe 650-0017, Japan, kusu@med.kobe-u.ac.jp.
FAU - Matsumiya, Wataru
AU  - Matsumiya W
AD  - Department of Surgery, Division of Ophthalmology, Kobe University Graduate School 
      of Medicine, Chuo-ku, Kobe 650-0017, Japan, kusu@med.kobe-u.ac.jp.
FAU - Azumi, Atsushi
AU  - Azumi A
AD  - Department of Ophthalmology, Kobe Kaisei Hospital, Nada-ku, Kobe 657-0068, Japan.
FAU - Nakamura, Makoto
AU  - Nakamura M
AD  - Department of Surgery, Division of Ophthalmology, Kobe University Graduate School 
      of Medicine, Chuo-ku, Kobe 650-0017, Japan, kusu@med.kobe-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20190320
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC6433110
OTO - NOTNLM
OT  - Behcet's disease
OT  - cyclosporine
OT  - efficacy
OT  - infliximab
OT  - safety
OT  - uveitis
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2019/04/10 06:00
MHDA- 2019/04/10 06:01
PMCR- 2019/03/20
CRDT- 2019/04/10 06:00
PHST- 2019/04/10 06:00 [entrez]
PHST- 2019/04/10 06:00 [pubmed]
PHST- 2019/04/10 06:01 [medline]
PHST- 2019/03/20 00:00 [pmc-release]
AID - opth-13-521 [pii]
AID - 10.2147/OPTH.S198648 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2019 Mar 20;13:521-527. doi: 10.2147/OPTH.S198648. eCollection 
      2019.